#3 - Vertex Pharmaceuticals (NASDAQ:VRTX)
The last of the big pharma companies on this list is Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). The company is a leader in cystic fibrosis therapeutics, with its flagship therapy Trikafta capturing 90% of the current patient population. In addition to looking to expand the label on Trikafta, Vertex has a triple-combination therapy for CF in its pipeline.
The takeaway is that the company will hold a leadership position in CF for years to come. That alone would inspire investor confidence. However, Vertex is also taking the lead in the area of precision medicine. It's partnership with CRSPR Therapeutics Inc. (NASDAQ: CRSP) has resulted in a first-of-its-kind gene therapy treatment, Casgevy, for sickle cell disease and beta-thalassemia.
The Vertex Pharmaceuticals analyst forecast on MarketBeat has a Moderate Buy rating on the stock with a price target of $485.91. However, since reporting earnings in July, sentiment has been mostly bullish. Analysts are raising their price targets for ABBV stock; HC Wainwright is the most bullish with a target price of $600.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read More - Current Price
- $448.03
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 18 Buy Ratings, 9 Hold Ratings, 3 Sell Ratings.
- Consensus Price Target
- $499.12 (11.4% Upside)
